TABLE 2.
Analysis of IHC Staining and HER2 FISH for all Tumor Types and Location
| Immunohistochemical Scoring Scheme | No. Cases (n = 164) | Positive (n = 16) | HER2 FISH (ASCO-CAP) Negative (n = 144) |
Equivocal (n = 5) |
|---|---|---|---|---|
| ASCO/CAP | 5 | 5 | 0 | 0 |
| 3+ | ||||
| 2+ | 5 | 2 | 3 | 0 |
| 1+ | 29 | 6 | 19 | 4 |
| 0 | 126 | 3 | 122* | 1 |
| ToGA | ||||
| 3+ | 10 | 10 | 0 | 0 |
| 2+ | 12 | 3 | 6 | 3 |
| 1+ | 18 | 0 | 18 | 1 |
| 0 | 124 | 3 | 120* | 1 |
*
Five cases which were negative by HER2 IHC had faint FISH signals which were uninterpretable.
ASCO/CAP indicates American Society of Clinical Oncology/College of American Pathologists; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.